SEC Company Response from Stoke Therapeutics, Inc. (STOK) (CIK 0001623526) (STOK) — Jun 14, 2019
Stoke Therapeutics, Inc. (STOK) (CIK 0001623526)
Date: June 14, 2019 · CIK: 0001623526 · Accession: 0001193125-19-173255
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-38938, 333-231700
Letter
Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford, MA 01730
June 14, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, NE
Washington, DC 20549
Attention:
Sonia Bednarowski
Justin Dobbie
Rolf Sunderwall
Jim Rosenberg
Re:
Stoke Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-231700) originally filed May 23, 2019, as amended, and corresponding Registration Statement on Form 8-A (File No. 001-38938) filed June 11, 2019
Requested Date: June 18, 2019
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
Stoke Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, Ms. Forbess at (415)-875-2420.
* * *
Sincerely,
STOKE THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Stoke Therapeutics, Inc. 45 Wiggins Avenue Bedford, MA 01730 June 14, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, NE Washington, DC 20549 Attention: Sonia Bednarowski Justin Dobbie Rolf Sunderwall Jim Rosenberg Re: Stoke Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-231700) originally filed May 23, 2019, as amended, and corresponding Registration Statement on Form 8-A (File No. 001-38938) filed June 11, 2019 Requested Date: June 18, 2019 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: Stoke Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable. The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, Ms. Forbess at (415)-875-2420. * * * Sincerely, STOKE THERAPEUTICS, INC. By: /s/ Stephen J. Tulipano Stephen J. Tulipano Chief Financial Officer cc: Edward M. Kaye, Chief Executive Officer Stoke Therapeutics, Inc. Robert A. Freedman, Esq. Effie Toshav, Esq. Julia Forbess, Esq. Fenwick & West LLP [Signature Page to Company Acceleration Request Letter]